Introduction {#Sec1}
============

The co-existence of type 2 diabetes mellitus (T2DM) and cardiovascular diseases has contributed to the annual increased number of percutaneous coronary interventions (PCI). With recent advances in interventional cardiology where PCI has become among the most preferred invasive strategy for majority of the patients, and with advances in adjunctive pharmacotherapy, several newer oral P2Y~12~ inhibitors have reached the market \[[@CR1]\].

Cangrelor is one of the P2Y~12~ inhibitors which have been approved for use by the Food and Drug Administration (FDA) since June 2015 \[[@CR2]\]. In contrast to the other P2Y~12~ inhibitors, this drug is available in intravenous form and has been administered along with aspirin or in combination with clopidogrel during coronary stent implantation \[[@CR3]\].

The CHAMPION PCI \[[@CR4]\], CHAMPION PHOENIX \[[@CR5]\], and CHAMPION PLATFORM \[[@CR6]\] trials were set up to study the potential effects of cangrelor during PCI. However, despite of the inclusion of a large number of patients with T2DM in those trials, the trials were based on the general population with cardiovascular diseases. There was no research based specifically on the use of cangrelor in T2DM participants with coronary heart disease undergoing PCI.

In this analysis, we aimed to compare the cardiovascular outcomes and bleeding events which were associated with the use of cangrelor versus clopidogrel in patients with T2DM 48 h after PCI.

Methods {#Sec2}
=======

Electronic Databases {#Sec3}
--------------------

The electronic databases MEDLINE (PubMed), [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov), EMBASE, and Cochrane central were searched for relevant publications comparing canagrelor with clopidogrel in the general population undergoing PCI.

Search Terms/Phrases and Mode of Search {#Sec4}
---------------------------------------

The aforementioned electronic databases were searched for English-language publications using the following common terms/phrases:Cangrelor, clopidogrel and percutaneous coronary intervention/PCICangrelor, clopidogrel and diabetes mellitusNewer antiplatelets and percutaneous coronary intervention/PCICangrelor, clopidogrel and coronary angioplastyCangrelor and diabetes mellitusAfter selecting relevant publications, the authors went through the list of references to search for additional relevant articles.

Inclusion and Exclusion Criteria {#Sec5}
--------------------------------

The inclusion criteria were as follows:Randomized controlled trials comparing cangrelor versus clopidogrel in patients undergoing PCITrials which also included patients with T2DMTrials whereby efficacy and bleeding outcomes were reportedTrials that reported outcomes at 48 h after PCI

The exclusion criteria were as follows:Observational studies (retrospective and prospective studies, reports, case studies)Meta-analyses and literature reviews as well as systematic reviewsStudies that did not include participants with T2DM for extractionStudies that did not report the expected efficacy and bleeding eventsRepeated studies

Data Extraction and Quality Assessment {#Sec6}
--------------------------------------

Five authors were involved in the whole data extraction process. First of all the number of patients with T2DM was extracted from each trial followed by the total number of events representing each outcome. Then other features including the type of participants, the baseline features, and the methodological quality of each trial were extracted. Any disagreement which was encountered was resolved by contacting and discussing with the corresponding author.

The methodological quality of the trials was assessed on the basis of the criteria recommended by the Cochrane Collaboration (low, moderate, or high risk bias) \[[@CR7]\].

Statistical Analysis {#Sec7}
--------------------

This meta-analysis was carried out with the latest RevMan software (5.30). Odds ratios (OR) and 95% confidence intervals (CI) were used to represent the data.

Heterogeneity was assessed by the Q statistic test (*P* \< 0.05 was considered statistically significant) and the *I*^2^ statistic test (greater the *I*^2^ value, greater the heterogeneity).

A fixed-effect statistical model was used.

Sensitivity analysis was carried out by a method of exclusion whereby each trial was excluded one by one and a new analysis was carried out each time to note any significant deviation from the main result.

Publication bias was visually assessed by observing funnel plots.

Compliance with Ethics Guidelines {#Sec8}
---------------------------------

Since in this analysis, no experiment was carried out using human or animal by any of the authors, ethical approval or board review approval was not required.

Results {#Sec9}
=======

Search Outcomes {#Sec10}
---------------

A total number of 465 publications were searched with reference to the PRISMA guideline \[[@CR8]\]. On the basis of an assessment of the titles and abstracts, 418 publications were eliminated since they did not meet the requirements of the current article.

Forty-seven full-text articles were assessed for eligibility.

Further articles were eliminated on the basis of the following criteria: meta-analyses (11), literature reviews (3), pooled analyses (7), did not report the relevant outcomes (3), observational cohorts (2), duplicated studies (18).

Finally only three trials \[[@CR4]--[@CR6]\] satisfied the inclusion and exclusion criteria and were selected for this analysis as demonstrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow diagram to represent the study selection

General Properties of the Trials {#Sec11}
--------------------------------

The general properties of the trials are listed in Table [1](#Tab1){ref-type="table"}. This analysis consisted of a total number of 5031 participants with T2DM (enrolled between the years 2006 and 2012) who underwent coronary angioplasty. Those patients were extracted from the general population undergoing PCI. A detailed list is shown in Table [1](#Tab1){ref-type="table"}.Table 1General properties of the trials which were included in this analysisTrialsTime period of patients' enrollmentNo. of T2DM participants assigned to cangrelor (*n*)No. of T2DM participants assigned to clopidogrel (*n*)Total no. of T2DM participants per trial (*n*)CHAMPION PCI \[[@CR4]\]2006--2009133413312665CHAMPION PHOENIX \[[@CR5]\]2010--2012330359689CHAMPION PLATFORM \[[@CR6]\]2006--20098158621677*T2DM* type 2 diabetes mellitus

After methodological quality assessment, the trials were judged to have reported low to moderate risk of bias based on the criteria set up by the Cochrane Collaboration.

Outcomes Reported in Each Trial {#Sec12}
-------------------------------

During the data extraction process, outcomes were separately extracted and studied for their presence in the other trials.

The outcomes reported by the trials are listed below and in Table [2](#Tab2){ref-type="table"}.Table 2Outcomes which were reported in the trialsTrialsType of participantsOutcomes reportedFollow-up time periodCHAMPION PCI \[[@CR4]\]T2DM patients with and without STEMIPrimary end point: composite of death, MI, and revascularization; MI, ischemia-driven revascularization, death from any cause, stent thrombosis, stroke, access site bleeding requiring radiological or surgical intervention, hematoma at puncture site ≤ 5 cm or \> 5 cm, intracranial hemorrhage, intraocular hemorrhage, bleeding requiring surgery, retroperitoneal hemorrhage, ecchymosis, epistaxis, oozing at puncture site, thrombocytopenia, any blood transfusion, any platelet transfusion, ACUITY-defined minor and major bleeding, GUSTO mild, moderate, and severe bleeding, TIMI-defined major and minor bleeding48 h after PCICHAMPION PHOENIX \[[@CR5]\]T2DM patients with stable coronary artery disease or acute coronary syndromePrimary end point: composite of death, MI, ischemia-driven revascularization, or stent thrombosis; MI, stent thrombosis, ischemia-driven revascularization, death from any cause, non-CABG-related bleeding, GUSTO-defined mild, moderate, and severe bleeding, TIMI-defined minor and major bleeding, ACUITY-defined major bleeding, any blood transfusion48 h after PCICHAMPION PLATFORM \[[@CR6]\]T2DM patients without STEMI or T2DM patients with unstable anginaPrimary end point: composite of death, MI, and revascularization; MI, ischemia-driven revascularization, death from any cause, stent thrombosis, access site bleeding requiring radiological or surgical intervention, hematoma at puncture site: ≤ 5 cm or \> 5 cm, intracranial hemorrhage, intraocular hemorrhage, bleeding requiring surgery, retroperitoneal hemorrhage, ecchymosis, epistaxis, oozing at puncture site, thrombocytopenia, any blood transfusion, any platelet transfusion, ACUITY-defined minor and major bleeding, GUSTO mild, moderate, and severe bleeding, TIMI-defined major and minor bleeding48 h after PCI*MI* myocardial infarction, *TIMI* thrombolysis in myocardial infarction, *CABG* coronary artery bypass surgery, *T2DM* type 2 diabetes mellitus, *STEMI* ST-elevation myocardial infarction, *PCI* percutaneous coronary intervention, *ACUITY* acute catheterization and urgent intervention triage strategy, *GUSTO* global use of strategies to open occluded arteries

The outcomes were as follows:Primary end points including composites of death, myocardial infarction (MI), ischemia-driven revascularization, and/or stent thrombosisMIDeath of any causeIschemia-driven revascularizationStent thrombosisAccess site bleeding requiring radiological or surgical interventionHematoma at puncture site ≤ 5 cm or \> 5 cmIntracranial hemorrhageIntraocular hemorrhageBleeding requiring surgeryRetroperitoneal hemorrhageEcchymosisEpistaxisOozing at puncture siteThrombocytopeniaAny blood transfusionACUITY (acute catheterization and urgent intervention triage strategy)-defined minor and major bleeding \[[@CR9]\]GUSTO (global use of strategies to open occluded arteries) mild, moderate and severe bleeding \[[@CR9]\]TIMI (thrombolysis in myocardial infarction)-defined major and minor bleeding \[[@CR9]\]The different types of bleeding have been defined \[[@CR9]\]. This analysis had a follow-up time period of 48 h after PCI.

Baseline Features of the Participants {#Sec13}
-------------------------------------

Table [3](#Tab3){ref-type="table"} lists the baseline characteristics of the participants with T2DM. A mean age of 62.0--64.0 years was reported among the participants. Male gender varied from 70.4% to 73.9%. Family history of coronary artery disease varied from 35.9% to 46.5%; 25.4% to 31.9% of the participants were smokers; 5.2% to 69.4% of the participants suffered from stable angina as reported in Table [3](#Tab3){ref-type="table"}.Table 3Baseline features of the participantsTrialsAge (years)Male (%)Family history of CAD (%)Smoking history (%)Stable angina (%)CA/CLCA/CLCA/CLCA/CLCA/CLCHAMPION PCI \[[@CR4]\]62.0/62.073.9/72.245.9/46.528.5/29.115.1/15.0CHAMPION PHOENIX \[[@CR5]\]64.0/64.072.5/71.9--25.4/25.769.4/63.4CHAMPION PLATFORM \[[@CR6]\]63.0/63.071.9/70.436.4/35.931.9/30.35.20/5.30*CA* cangrelor, *CL* clopidogrel, *CAD* coronary artery disease

Results of This Analysis {#Sec14}
------------------------

Compared to clopidgrel, use of cangrelor in these patients with T2DM was not associated with significantly different primary end point (OR 0.94, 95% CI 0.75--1.16; *P* = 0.55), MI (OR 0.96, 95% CI 0.76--1.20; *P* = 0.71), all-cause death (OR 0.70, 95% CI 0.25--1.96; *P* = 0.49), ischemia-driven revascularization (OR 0.66, 95% CI 0.32--1.36; *P* = 0.26), and stent thrombosis (OR 0.45, 95% CI 0.17--1.17; *P* = 0.10) as demonstrated in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Comparison between cangrelor and clopidogrel for cardiovascular outcomes

When cangrelor was used in these patients with T2DM in comparison to clopidogrel, TIMI-defined major and minor bleedings were similarly manifested: (OR 1.02, 95% CI 0.38--2.74; *P* = 0.96) and (OR 1.39, 95% CI 0.70--2.79; *P* = 0.35), respectively, as shown in Fig. [3](#Fig3){ref-type="fig"}. GUSTO-defined moderate and severe bleeding were also not significantly different: (OR 1.36, 95% CI 0.70--2.67; *P* = 0.37) and (OR 1.21, 95% CI 0.41--3.59; *P* = 0.74), respectively, as shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Comparison between cangrelor and clopidogrel for important bleeding events

However, GUSTO-defined mild bleeding and ACUITY-defined major and minor bleedings were significantly in favor of clopidogrel in comparison to cangrelor in these patients with T2DM: (OR 1.28, 95% CI 1.09--1.50; *P* = 0.003), (OR 1.43, 95% CI 1.05--1.94; *P* = 0.02), and (OR 1.23, 95% CI 1.04--1.46; *P* = 0.02), respectively, as shown in Fig. [3](#Fig3){ref-type="fig"}.

Access site bleeding requiring radiological or surgical intervention (OR 0.68, 95% CI 0.19--2.43; *P* = 0.56), hematoma at puncture site ≤ 5 cm (OR 1.21, 95% CI 0.86--1.71; *P* = 0.28), hematoma at puncture site \> 5 cm (OR 1.26, 95% CI 0.95--1.68; *P* = 0.11), intracranial hemorrhage (OR 1.72, 95% CI 0.23--13.06; *P* = 0.60), intraocular hemorrhage (OR 3.00, 95% CI 0.12--73.60; *P* = 0.50), bleeding requiring surgery (OR 1.03, 95% CI 0.14--7.30; *P* = 0.98), retroperitoneal hemorrhage (OR 1.52, 95% CI 0.43--5.39; *P* = 0.52), ecchymosis (OR 1.32, 95% CI 1.00--1.75; *P* = 0.05), epistaxis (OR 0.46, 95% CI 0.16--1.33; *P* = 0.15), thrombocytopenia (OR 1.02, 95% CI 0.21--5.05; *P* = 0.98), and any blood transfusion (OR 1.22, 95% CI 0.68--2.18; *P* = 0.51) were also assessed in these patients with T2DM, without any significant difference with either cangrelor or clopidogrel as illustrated in Fig. [4](#Fig4){ref-type="fig"}.Fig. 4Comparison between cangrelor and clopidogrel for other bleeding events

The results have been listed in Table [4](#Tab4){ref-type="table"}.Table 4Results of this meta-analysisOutcomes which were assessedOR \[95% CI\]*P* value*I*^2^ value (%)Primary end point0.94 \[0.75--1.16\]0.550Myocardial infarction0.96 \[0.76--1.20\]0.710Death of any cause0.70 \[0.25--1.96\]0.490Ischemia-driven revascularization0.66 \[0.32--1.36\]0.260Stent thrombosis0.45 \[0.17--1.17\]0.100Assess site bleeding requiring radiological or surgical intervention0.68 \[0.19--2.43\]0.560Hematoma at puncture site ≤ 5 cm1.21 \[0.86--1.71\]0.280Hematoma at puncture site \> 5 cm1.26 \[0.95--1.68\]0.1122Intracranial hemorrhage1.72 \[0.23--13.06\]0.600Intraocular hemorrhage3.00 \[0.12--73.60\]0.50--Bleeding requiring surgery1.03 \[0.14--7.30\]0.980Retroperitoneal hemorrhage1.52 \[0.43--5.39\]0.520Ecchymosis1.32 \[1.00--1.75\]0.050Epistaxis0.46 \[0.16--1.33\]0.150Thrombocytopenia1.02 \[0.21--5.05\]0.980Any blood transfusion1.22 \[0.68--2.18\]0.510ACUITY-defined major bleeding1.43 \[1.05--1.94\]0.020ACUITY-defined minor bleeding1.23 \[1.04--1.46\]0.020GUSTO-defined mild bleeding1.28 \[1.09--1.50\]0.0039GUSTO-defined moderate bleeding1.36 \[0.70--2.67\]0.370GUSTO-defined severe bleeding1.21 \[0.41--3.59\]0.740TIMI-defined major bleeding1.02 \[0.38--2.74\]0.960TIMI-defined minor bleeding1.39 \[0.70--2.79\]0.350*ACUITY* acute catheterization and urgent intervention triage strategy, *GUSTO* global use of strategies to open occluded arteries, *TIMI* thrombolysis in myocardial infarction, *OR* odds ratios, *CI* confidence intervals

Publication Bias {#Sec15}
----------------

Publication bias was assessed by visualizing the funnel plot as a result of the small volume of trials. A symmetrical funnel plot as shown in Fig. [5](#Fig5){ref-type="fig"} demonstrated very low evidence of publication bias during assessment of all the clinical end points studied in this meta-analysis.Fig. 5Funnel plot representing publication bias

Discussion {#Sec16}
==========

The effect of cangrelor in T2DM patients undergoing PCI has seldom been studied \[[@CR10]\]. In this analysis, the use of cangrelor was compared to clopidogrel during PCI in patients with T2DM. The current results showed similar efficacy outcomes; however, cangrelor was associated with significantly higher GUSTO-defined mild and ACUITY-defined major and minor bleedings, whereas TIMI-defined bleedings were similar to those of clopidogrel. Other outcomes such as intracranial hemorrhage, epistaxis, access site bleeding, and hematoma were not significantly different in these patients with T2DM. However, these safety outcomes associated with bleeding events should be further studied since only three trials were available for inclusion in this analysis. Lack of data and studies might have an effect on these outcomes during analysis.

The CHAMPION PHOENIX trial showed cangrelor to improve anti-ischemic events in comparison to clopidogrel without even increasing the bleeding risk in the participants which were involved in the trial \[[@CR11]\]. This effect was observed irrespective of the use of glycoprotein IIb/IIIa inhibitors \[[@CR12]\]. Patients with T2DM were combined and mixed with patients without diabetes mellitus and assessed.

The CHAMPION PHOENIX trial also demonstrated cangrelor to significantly reduce the risk of stent thrombosis in the general population of patients with stable angina and acute coronary syndrome \[[@CR13]\]. The trial also showed no influence of cangrelor on GUSTO moderate/severe bleeding when compared to clopidogrel. Our analysis also showed no influence of cangrelor on moderate/severe GUSTO-defined bleeding. However, cangrelor significantly increased GUSTO-defined mild bleeding in these patients with T2DM. In addition, our current analysis did not show cangrelor to significantly decrease stent thrombosis in these patients with T2DM. The reason behind this could be the high platelet activity or platelet dysfunction or platelet hypo-responsiveness in patients with T2DM \[[@CR14], [@CR15]\].

In a recent meta-analysis which compared the benefits of newer P2Y~12~ inhibitors with that of clopidogrel and which involved about 71,097 participants, the authors concluded that newer P2Y~12~ inhibitors did decrease the risk of death post intervention; however, their safety outcomes should be further investigated \[[@CR16]\]. In addition, a meta-analysis by Bellemain-Appaix et al. was also in favor of newer P2Y~12~ inhibitors in comparison to clopidogrel following PCI. Their analysis showed newer P2Y~12~ inhibitors to decrease mortality, and the authors stated that this result was favorable, especially in patients with STEMI \[[@CR17]\].

Cangrelor has also shown beneficial effects when used in combination with glycoprotein IIb/IIIa, bivalirudin, and other antithrombotic agents during the invasive procedure. The use of this potential intravenous drug should be further investigated, especially in patients with T2DM.

Limitations {#Sec17}
-----------

Limitations were associated first of all with the small sample size of patients with T2DM. In addition, longer follow-up time periods were not available for study in this analysis. Patients from the general population undergoing PCI were included in this analysis irrespective of whether they were stable or unstable angina or acute coronary syndrome participants. In addition, the duration of diabetes mellitus and the number of participants on insulin therapy were not reported in this current analysis. Also, in the CHAMPION PLATFORM trial, the participants who were assigned to the cangrelor group also received clopidogrel as a second antiplatelet agent. This might be another limitation of this analysis. Finally, there might not have been sufficient data to assess all the required end points well. The number of trials was also low but there was nothing which could be done to improve this limitation since only three trials based on this comparison were published.

Conclusions {#Sec18}
===========

In these patients with T2DM, cangrelor was comparable to clopidogrel in terms of efficacy at 48 h following PCI. However, it was associated with significantly higher mild GUSTO bleeding and major and minor ACUITY bleeding, therefore requiring further workups on its safety side. This hypothesis should be explored further and confirmed in other forthcoming trials based strictly on patients with T2DM.
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:   Food and Drug Administration
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:   Type 2 diabetes mellitus
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